BRCA2 and familial pancreatic carcinoma: The effect of fluozoparib on xenograft-tumors in nude mice with injected MX-1 cell (breast cancer BRCA1/2 mutation cell), MDA-MB-436 cell (breast cancer BRCA2 mutation cell)), capan-1 cell (pancreatic cancer cell with BRCA1 mutation) and SW-620 cell (colon cancer cell with reduced BRCA expression) was conducted [16], and the result showed significantly synergetic effect of fluzoparib and TMZ against the tumor cells above with obvious dose-dependent, and the synergetic effect may cause partial tumor regression.